Compare Mesoblast Limited (MESO) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vipshop Holdings Ltd - ADR — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Vipshop Holdings Ltd - ADR trades at $14.63 (market cap $7.01B). The key difference: Vipshop Holdings Ltd - ADR is far larger — about 3.2× Mesoblast Limited's market cap, and Vipshop Holdings Ltd - ADR pays a 4.25% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | VIPS | |
|---|---|---|
Market Cap | $2.17B | $7.01B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $20.68 |
52-Week Low | $12.88 | $12.92 |
Enterprise Value | $2.17B | $3.60B |
Dividend Yield | — | 4.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Vipshop (VIPS) trades at $14.56, up 0.41% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 7.07% net income margin and attractive valuation ratios including a P/E of 6.61. Recent Q1 2026 earnings met expectations, and the company is pursuing growth through an outlet store REIT spin-off strategy. Revenue has stabilized around $106 billion after a slight decline from 2023 peaks.
Outlook remains positive given low valuations and analyst consensus, but risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds. The stock offers value opportunity if execution on outlet strategy drives growth, though investors should monitor revenue trends and industry challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
